Found 1 Presentation For Request "1809P"
1809P - Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy
- Carly C. Barron (Toronto, Canada)
Abstract
Background
Activating mutations in
Methods
Patients with
Results
We identified 123 patients, 42 (37%) mPFS by
Group ORR mPFS (months, univariate HR, p-value) G12C, PD-L1 high (n=24) 65% 23.5 (0.2, p<0.001) G12C, PD-L1 low (n=14) 21% 4.7 (0.7, p=0.3) Transversion mutation, PD-L1 high (n=23) (G12R, G12V, G12A) 43% 4.9 (0.4, p=0.02) Transversion mutation, PD-L1 low (n=25) (G12D, G12S) 16% 4.0 (0.7, p=0.3) Transition mutation (n=20) 20% 2.6 (ref)
Conclusions
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.